Skip to main content
Need immediate help?SAMHSA Helpline: 1-800-662-4357|988 Crisis Lifeline|Text HOME to 741741

Modern treatments

The connection between Ozempic and alcohol cravings: What the research shows

Published March 12, 2025 · 8 min read · Updated April 2026
Reviewed for accuracy by licensed clinical professionals. Editorial process.

One of the most unexpected findings in recent medicine has been the anecdotal and emerging scientific reports that GLP-1 receptor agonists — primarily known as diabetes and weight loss medications (Ozempic, Wegovy, Mounjaro) — appear to reduce alcohol cravings and consumption in many users. This was not what the medications were designed for, and the research is still early, but the implications for addiction treatment could be significant.

What users are reporting

Across social media, patient forums, and increasingly in clinical reports, people taking GLP-1 medications describe dramatically reduced interest in alcohol. Not just physical cravings — a fundamental shift in the appeal of drinking. Phrases like "alcohol just stopped being interesting," "I can have one drink and stop," and "I don't think about drinking anymore" appear repeatedly. These reports span people with and without clinical alcohol use disorder.

What the science suggests

GLP-1 receptors are present not just in the gut and pancreas (where they regulate appetite and blood sugar) but also in the brain's reward centers — the same regions involved in addiction. Animal studies dating back over a decade show that GLP-1 agonists reduce alcohol consumption, reduce the rewarding effects of alcohol, and reduce alcohol-seeking behavior after a period of abstinence. Several human clinical trials are underway, and early results have been promising, showing significant reductions in heavy drinking days and overall alcohol consumption.

What this means and does not mean

It is too early to call GLP-1 medications an addiction treatment. No GLP-1 medication is FDA-approved for alcohol use disorder. The existing evidence-based medications (naltrexone, acamprosate, disulfiram) remain the standard of care. If you are on a GLP-1 medication for diabetes or weight management and notice reduced interest in alcohol, that is consistent with the emerging data and is worth discussing with your doctor. If you are seeking treatment specifically for alcohol use disorder, work with an addiction specialist who can prescribe established medications while monitoring ongoing research developments.

Treatment facilities

Shelby County Treatment Center
Alabaster, AL
Call 205-216-0200
Lighthouse of Tallapoosa County Inc
Alexander City, AL
Call 256-234-4894
South Central Alabama MHC
Andalusia, AL
Call 334-428-5050
Anniston Fellowship House Inc
Anniston, AL
Call 256-236-7229
Browse all facilities →

Authoritative sources

This article references guidelines from: NIDA · SAMHSA · CDC · FDA · ASAM

Frequently asked questions

Does Ozempic help with alcohol addiction?
Emerging research and widespread anecdotal reports suggest GLP-1 medications reduce alcohol cravings, but no GLP-1 medication is currently FDA-approved for alcohol use disorder. Clinical trials are ongoing.
How does Ozempic affect alcohol cravings?
GLP-1 receptors exist in the brain's reward centers. Stimulating these receptors appears to reduce the rewarding effects of alcohol, potentially through the same mechanisms that reduce food reward and appetite.
Should I take Ozempic for drinking?
GLP-1 medications are not approved for alcohol treatment. If you have alcohol use disorder, consult an addiction specialist about established treatments (naltrexone, acamprosate). If you're already on Ozempic and notice reduced drinking, discuss this with your doctor.

Disclaimer: Informational only. Not medical advice. SAMHSA: 1-800-662-4357.